CMS Delays Inclusion Of Oral-Only ESRD Drugs In Final Bundled Payment Rule For Medicare
This article was originally published in The Pink Sheet Daily
Executive Summary
Inclusion of oral-only drugs in bundled payment will be delayed until 2014, allowing CMS to address pricing and data issues, but the decision does not alter the agency's interpretation that oral-only drugs should be a part of the bundle.
You may also be interested in...
Bill To Overturn Delay In Bundling Oral-Only Drugs For ESRD Introduced
Rep. Peter Welch introduces a bill that would overturn a provision in the American Taxpayer Relief Act delaying the bundling of oral-only drugs for ESRD treatment, such as Amgen’s Sensipar, until 2016.
Including Oral-Only ESRD Drugs In Payment Bundle Could Harm Access: GAO
The inclusion of oral-only end-stage renal disease drugs in the Medicare prospective payment system beginning in 2014 could have a negative effect on access to these drugs if facilities consider bundled reimbursement to be inadequate to cover their cost, according to an analysis by the Government Accountability Office.
Including Oral-Only ESRD Drugs In Payment Bundle Could Harm Access: GAO
The inclusion of oral-only end-stage renal disease drugs in the Medicare prospective payment system beginning in 2014 could have a negative effect on access to these drugs if facilities consider bundled reimbursement to be inadequate to cover their cost, according to an analysis by the Government Accountability Office.